{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:31:09Z","timestamp":1793377869917,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ejso.2026.112003","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T15:58:55Z","timestamp":1784044735000},"page":"112003","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Perihilar cholangiocarcinoma: Expanding the role of liver transplantation in the era of multimodal therapy"],"prefix":"10.1016","volume":"52","author":[{"given":"Jia-Yu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1444-4373","authenticated-orcid":false,"given":"Chuan-Jin","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Ping","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-Yong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ejso.2026.112003_bib1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib2","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/00000658-199201000-00005","article-title":"Management strategies in resection for hilar cholangiocarcinoma","volume":"215","author":"Bismuth","year":"1992","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.ejso.2026.112003_bib4","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/S1470-2045(25)00376-6","article-title":"Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study","volume":"26","author":"Shi","year":"2025","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2026.112003_bib5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.surg.2022.09.028","article-title":"Clinical feasibility of curative surgery after nab-paclitaxel plus gemcitabine-cisplatin chemotherapy in patients with locally advanced cholangiocarcinoma","volume":"173","author":"Choi","year":"2023","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.ejso.2026.112003_bib6","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/00007890-200004270-00019","article-title":"Liver transplantation for cholangiocarcinoma: results in 207 patients","volume":"69","author":"Meyer","year":"2000","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ejso.2026.112003_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/lv.2000.6143","article-title":"Prolonged disease-free survival after orthotopic liver transplantation plus adjuvant chemoirradiation for cholangiocarcinoma","volume":"6","author":"De Vreede","year":"2000","journal-title":"Liver Transplant"},{"issue":"2","key":"10.1016\/j.ejso.2026.112003_bib8","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.sla.0000108702.45715.81","article-title":"Spanish experience in liver transplantation for hilar and peripheral cholangiocarcinoma","volume":"239","author":"Robles","year":"2004","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ejso.2026.112003_bib9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1034\/j.1600-6143.2002.20812.x","article-title":"Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma","volume":"2","author":"Sudan","year":"2002","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ejso.2026.112003_bib26","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.sla.0000179678.13285.fa","article-title":"Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma","volume":"242","author":"Rea","year":"2005","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112003_bib30","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jss.2019.04.023","article-title":"Downstaging locally advanced cholangiocarcinoma pre-liver transplantation: a prospective pilot study","volume":"242","author":"Wong","year":"2019","journal-title":"J Surg Res"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib24","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1053\/j.gastro.2012.04.008","article-title":"Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers","volume":"143","author":"Darwish","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejso.2026.112003_bib81","article-title":"Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma","author":"Dong","year":"2025","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/SLA.0000000000005641","article-title":"Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study","volume":"276","author":"Breuer","year":"2022","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jamcollsurg.2019.12.037","article-title":"Living donor liver transplantation for perihilar cholangiocarcinoma: outcomes and complications","volume":"231","author":"Tan","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"10","key":"10.1016\/j.ejso.2026.112003_bib80","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/TP.0000000000003114","article-title":"Neoadjuvant chemoradiotherapy and liver transplantation for unresectable hilar cholangiocarcinoma: the Irish experience of the Mayo protocol","volume":"104","author":"Zaborowski","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ejso.2026.112003_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001760","article-title":"Neoadjuvant multiagent systemic therapy approach to liver transplantation for perihilar cholangiocarcinoma","volume":"11","author":"Soliman","year":"2025","journal-title":"Transplant Direct"},{"issue":"2","key":"10.1016\/j.ejso.2026.112003_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrad025","article-title":"Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: Multicentre, retrospective cohort study","volume":"7","author":"Hoogwater","year":"2023","journal-title":"BJS Open"},{"issue":"4","key":"10.1016\/j.ejso.2026.112003_bib42","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/jhbp.12121","article-title":"Safety and efficacy of living donor liver transplantation for unresectable perihilar cholangiocarcinoma: a single center prospective study","volume":"32","author":"Ito","year":"2025","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"4","key":"10.1016\/j.ejso.2026.112003_bib92","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.hpb.2021.08.940","article-title":"Single-center experience of liver transplantation for perihilar cholangiocarcinoma","volume":"24","author":"Ahmed","year":"2022","journal-title":"HPB (Oxford)"},{"issue":"7","key":"10.1016\/j.ejso.2026.112003_bib36","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s13304-024-01889-1","article-title":"The Italian experience on liver transplantation for unresectable peri-hilar cholangiocarcinoma: a national survey and future perspectives","volume":"76","author":"Gringeri","year":"2024","journal-title":"Updates Surg"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib29","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/SLA.0000000000002574","article-title":"Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease","volume":"267","author":"Ethun","year":"2018","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib10","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2026.112003_bib11","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1136\/gutjnl-2023-330029","article-title":"British society of gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","volume":"73","author":"Rushbrook","year":"2023","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib13","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/ot9.0000000000000112","article-title":"Controversy and progress in surgical treatment of hilar cholangiocarcinoma","volume":"12","author":"Chen","year":"2026","journal-title":"Oncology and Translational Medicine"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/SLA.0000000000004821","article-title":"Extended right-hemihepatectomy is preferred for perihilar cholangiocarcinoma","volume":"274","author":"Lang","year":"2021","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2026.112003_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/SLA.0000000000004322","article-title":"Combined vascular resection for locally advanced perihilar cholangiocarcinoma","volume":"275","author":"Mizuno","year":"2022","journal-title":"Ann Surg"},{"issue":"3","key":"10.1016\/j.ejso.2026.112003_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrad024","article-title":"Surgical treatment of hilar cholangiocarcinoma: retrospective analysis","volume":"7","author":"Li","year":"2023","journal-title":"BJS Open"},{"issue":"14","key":"10.1016\/j.ejso.2026.112003_bib17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"10391","key":"10.1016\/j.ejso.2026.112003_bib18","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejso.2026.112003_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.ejso.2026.112003_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103706","article-title":"Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets","volume":"9","author":"Kehmann","year":"2024","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.ejso.2026.112003_bib21","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/S1470-2045(21)00336-3","article-title":"Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study","volume":"22","author":"Javle","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib89","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.24.00337","article-title":"Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: clinical and biomarker data from the randomized phase II IMbrave151 trial","volume":"43","author":"Macarulla","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib90","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/s41392-025-02356-y","article-title":"First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study","volume":"10","author":"Shi","year":"2025","journal-title":"Signal Transduct Targeted Ther"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib91","doi-asserted-by":"crossref","first-page":"5559","DOI":"10.1038\/s41467-025-60119-3","article-title":"Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial","volume":"16","author":"Li","year":"2025","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ejso.2026.112003_bib22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S0002-9610(05)80696-8","article-title":"Is liver transplantation indicated for cholangiocarcinoma?","volume":"166","author":"Goldstein","year":"1993","journal-title":"Am J Surg"},{"issue":"6","key":"10.1016\/j.ejso.2026.112003_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156127","article-title":"Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival","volume":"11","author":"Mantel","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib25","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/17474124.2021.1890584","article-title":"Liver transplantation for perihilar cholangiocarcinoma: patient selection and outcomes","volume":"15","author":"Acher","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib27","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jamcollsurg.2012.03.014","article-title":"Neoadjuvant therapy and liver transplantation for hilar cholangiocarcinoma: is pretreatment pathological confirmation of diagnosis necessary?","volume":"215","author":"Rosen","year":"2012","journal-title":"J Am Coll Surg"},{"issue":"17","key":"10.1016\/j.ejso.2026.112003_bib28","doi-asserted-by":"crossref","first-page":"6028","DOI":"10.3390\/jcm14176028","article-title":"Advances in endoscopic diagnosis and management of cholangiocarcinoma","volume":"14","author":"Chaudhary","year":"2025","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.ejso.2026.112003_bib31","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/jso.24833","article-title":"Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada","volume":"117","author":"Loveday","year":"2018","journal-title":"J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhep.2025.03.007","article-title":"EASL clinical practice guidelines on the management of extrahepatic cholangiocarcinoma","volume":"83","year":"2025","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.ejso.2026.112003_bib33","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/SLA.0000000000002964","article-title":"Is it time to abandon the milan criteria?: results of a bicoastal US collaboration to redefine hepatocellular carcinoma liver transplantation selection policies","volume":"268","author":"Halazun","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112003_bib34","doi-asserted-by":"crossref","DOI":"10.1097\/ot9.0000000000000123","article-title":"HCC perioperative immunotherapy: insights from expert consensus on multidisciplinary collaboration in perioperative immunotherapy for hepatocellular carcinoma (2025 edition)","author":"Yuan","year":"2025","journal-title":"Oncology and Translational Medicine"},{"issue":"11","key":"10.1016\/j.ejso.2026.112003_bib37","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/lt.21887","article-title":"Extended bile duct resection and [corrected] liver and transplantation in patients with hilar cholangiocarcinoma: long-term results","volume":"15","author":"Seehofer","year":"2009","journal-title":"Liver Transplant"},{"issue":"6","key":"10.1016\/j.ejso.2026.112003_bib40","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/COC.0000000000001002","article-title":"Neoadjuvant therapy regimens for hilar cholangiocarcinoma before liver transplant","volume":"46","author":"Keltner","year":"2023","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/lt.23757","article-title":"Neoadjuvant stereotactic body radiation therapy, capecitabine, and liver transplantation for unresectable hilar cholangiocarcinoma","volume":"20","author":"Welling","year":"2014","journal-title":"Liver Transplant"},{"issue":"10","key":"10.1016\/j.ejso.2026.112003_bib43","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/lt.21107","article-title":"Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma","volume":"13","author":"Mantel","year":"2007","journal-title":"Liver Transplant"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib44","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000347207","article-title":"Liver transplantation for perihilar cholangiocarcinoma","volume":"31","author":"Gores","year":"2013","journal-title":"Dig Dis"},{"issue":"6","key":"10.1016\/j.ejso.2026.112003_bib45","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/TP.0000000000003212","article-title":"Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: Working group report from the ILTS transplant oncology consensus conference","volume":"104","author":"Sapisochin","year":"2020","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.ejso.2026.112003_bib46","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/hep.25629","article-title":"Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma","volume":"56","author":"Darwish","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib47","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4291\/wjgp.v12.i5.84","article-title":"Cholangiocarcinoma and liver transplantation: what we know so far?","volume":"12","author":"Safarpour","year":"2021","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib48","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/lt.22462","article-title":"Impact of neoadjuvant chemoradiation on the tumor burden before liver transplantation for unresectable cholangiocarcinoma","volume":"18","author":"Panjala","year":"2012","journal-title":"Liver Transplant"},{"key":"10.1016\/j.ejso.2026.112003_bib50","article-title":"Transplantation within 6 months of registration does not enhance survival for patients with perihilar cholangiocarcinoma","volume":"4","author":"Nasser-Ghodsi","year":"2024","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib51","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/hpb.12082","article-title":"Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience","volume":"16","author":"Duignan","year":"2014","journal-title":"HPB (Oxford)"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib52","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/liv.15474","article-title":"Immune checkpoint inhibitors in malignancies after liver transplantation: better safe or sorry?","volume":"43","author":"Vogel","year":"2023","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.ejso.2026.112003_bib53","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1001\/jamaoncol.2019.0413","article-title":"PD-1 immune checkpoint inhibitors and immune-related adverse events: understanding the upside of the downside of checkpoint blockade","volume":"5","author":"Davar","year":"2019","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2026.112003_bib54","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/j.ajt.2024.04.007","article-title":"Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: a multicenter, retrospective cohort study","volume":"24","author":"Guo","year":"2024","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib55","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jhep.2024.01.011","article-title":"Immunotherapy and transplantation for hepatocellular carcinoma","volume":"80","author":"Tabrizian","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.ejso.2026.112003_bib56","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jhep.2023.01.030","article-title":"Liver transplantation immunology: immunosuppression, rejection, and immunomodulation","volume":"78","author":"Montano-Loza","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.ejso.2026.112003_bib57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s12032-019-1316-7","article-title":"Liver graft rejection following immune checkpoint inhibitors treatment: a review","volume":"36","author":"Hu","year":"2019","journal-title":"Med Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112003_bib93","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jhep.2024.09.003","article-title":"Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study","volume":"82","author":"Tabrizian","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jhep.2024.06.042","article-title":"Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: a systematic review and individual patient data meta-analysis","volume":"82","author":"Rezaee-Zavareh","year":"2025","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib64","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1097\/HEP.0000000000001289","article-title":"Determining safe washout period for immune checkpoint inhibitors prior to liver transplantation: an international retrospective cohort study","volume":"82","author":"Moeckli","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib75","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1186\/s12916-025-04352-z","article-title":"Immune checkpoint inhibitors use in liver transplantation for hepatocellular carcinoma: a global cohort study","volume":"23","author":"Ma","year":"2025","journal-title":"BMC Med"},{"issue":"7","key":"10.1016\/j.ejso.2026.112003_bib58","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2026.112003_bib59","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2024.05.037","article-title":"Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation","volume":"81","author":"Li","year":"2024","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.ejso.2026.112003_bib60","article-title":"Liver resection and transplantation in the era of checkpoint inhibitors","volume":"6","author":"Tabrizian","year":"2024","journal-title":"JHEP Rep"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2023.100817","article-title":"Immunosuppression for older liver transplant recipients","volume":"38","author":"De Simone","year":"2024","journal-title":"Transplant Rev"},{"issue":"4","key":"10.1016\/j.ejso.2026.112003_bib63","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.transproceed.2023.03.064","article-title":"Optimizing the safe washout period for liver transplantation following immune checkpoint inhibitors with atezolizumab, nivolumab, or pembrolizumab","volume":"55","author":"Kuo","year":"2023","journal-title":"Transplant Proc"},{"issue":"6","key":"10.1016\/j.ejso.2026.112003_bib65","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/apt.70333","article-title":"Review article: liver transplantation for hepatocellular carcinoma in the era of immune checkpoint inhibitors","volume":"62","author":"Kulkarni","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.ejso.2026.112003_bib66","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2007.07.003","article-title":"Cholangiocarcinoma: is transplantation an option? For whom?","volume":"47","author":"Gores","year":"2007","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ejso.2026.112003_bib67","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/SLA.0000000000006815","volume":"282","author":"Li","year":"2025","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2026.112003_bib68","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ejca.2022.08.010","article-title":"Immune checkpoint blockade for organ-transplant recipients with cancer: a review","volume":"175","author":"R\u00fcnger","year":"2022","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejso.2026.112003_bib69","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1111\/apt.15253","article-title":"Systematic review with meta-analysis: Sirolimus- or everolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma","volume":"49","author":"Grigg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.ejso.2026.112003_bib70","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/lt.26387","article-title":"Sirolimus or everolimus improves survival after liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis","volume":"28","author":"Yan","year":"2022","journal-title":"Liver Transplant"},{"issue":"12","key":"10.1016\/j.ejso.2026.112003_bib71","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/cancers14122890","article-title":"The role of immunosuppression for recurrent cholangiocellular carcinoma after liver transplantation","volume":"14","author":"G\u00fcl-Klein","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejso.2026.112003_bib72","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1520083","article-title":"Transplant oncology and anti-cancer immunosuppressants","volume":"15","author":"Kong","year":"2025","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11810-z","article-title":"The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation","volume":"7","author":"Ravaioli","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ejso.2026.112003_bib74","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(18)30915-X","article-title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study","volume":"20","author":"Primrose","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib76","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/liv.15419","article-title":"Immune checkpoint inhibitors in malignancies after liver transplantation: a systematic review and pooled analysis","volume":"43","author":"Kayali","year":"2023","journal-title":"Liver Int"},{"issue":"11","key":"10.1016\/j.ejso.2026.112003_bib77","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s11605-020-04721-4","article-title":"Liver transplantation for peri-hilar cholangiocarcinoma","volume":"24","author":"Tan","year":"2020","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib78","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ajt.12907","article-title":"A complete treatment of adult living donor liver transplantation: a review of surgical technique and current challenges to expand indication of patients","volume":"15","author":"Lee","year":"2015","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.ejso.2026.112003_bib79","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/SLA.0000000000001383","article-title":"Defining long-term outcomes with living donor liver transplantation in North America","volume":"262","author":"Olthoff","year":"2015","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ejso.2026.112003_bib82","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/PAS.0000000000000588","article-title":"Prognostic significance of the histologic response of perihilar cholangiocarcinoma to preoperative neoadjuvant chemoradiation in liver explants","volume":"40","author":"Lehrke","year":"2016","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1016\/j.ejso.2026.112003_bib83","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/01.tp.0000253551.43583.d1","article-title":"Predictors of disease recurrence following neoadjuvant chemoradiotherapy and liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"82","author":"Heimbach","year":"2006","journal-title":"Transplantation"},{"issue":"12","key":"10.1016\/j.ejso.2026.112003_bib84","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/tri.12640","article-title":"Portal vein encasement predicts neoadjuvant therapy response in liver transplantation for perihilar cholangiocarcinoma protocol","volume":"28","author":"Bhat","year":"2015","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.ejso.2026.112003_bib85","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/SLA.0000000000003801","article-title":"Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma","volume":"273","author":"Cambridge","year":"2021","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2026.112003_bib86","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jhbp.870","article-title":"Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition","volume":"28","author":"Nagino","year":"2021","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.ejso.2026.112003_bib87","article-title":"Improved liver transplant outcomes for patients with hilar cholangiocarcinoma following implementation of the MMAT-3 policy","volume":"6","author":"Shaikh","year":"2025","journal-title":"Liver Transplant"},{"issue":"10372","key":"10.1016\/j.ejso.2026.112003_bib88","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0140-6736(22)02038-4","article-title":"Hepatobiliary and pancreatic oncology group of the japan clinical oncology group (JCOG-HBPOG). Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"401","author":"Nakachi","year":"2023","journal-title":"Lancet"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798326006220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:33:34Z","timestamp":1793374414000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798326006220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":93,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0748798326006220"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112003","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Perihilar cholangiocarcinoma: Expanding the role of liver transplantation in the era of multimodal therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2026.112003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"112003"}}